Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
- ByReuters-
By Manas Mishra (Reuters) - Pfizer Inc (NYSE:PFE)'s $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher...